• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
A new peg-filgrastim biosimilar, mecapegfilgrastim for primary prophylaxis of chemotherapy-related neutropenia is now available.一种用于化疗相关中性粒细胞减少症一级预防的新型聚乙二醇化非格司亭生物类似药——美卡非格司亭现已上市。
Ann Transl Med. 2020 Mar;8(5):166. doi: 10.21037/atm.2019.10.61.
2
Efficacy and safety of mecapegfilgrastim for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer: a randomized, multicenter, active-controlled phase III trial.甲磺酸培非格司亭预防乳腺癌患者化疗引起的中性粒细胞减少症的疗效和安全性：一项随机、多中心、活性药物对照的III期试验
Ann Transl Med. 2019 Sep;7(18):482. doi: 10.21037/atm.2019.07.95.
3
A Randomized Multicenter Phase III Study of Single Administration of Mecapegfilgrastim (HHPG-19K), a Pegfilgrastim Biosimilar, for Prophylaxis of Chemotherapy-Induced Neutropenia in Patients With Advanced Non-Small-Cell Lung Cancer (NSCLC).培非格司亭生物类似药美卡培非格司亭（HHPG-19K）单次给药用于预防晚期非小细胞肺癌（NSCLC）患者化疗所致中性粒细胞减少的随机多中心III期研究。
Clin Lung Cancer. 2016 Mar;17(2):119-27. doi: 10.1016/j.cllc.2015.12.002. Epub 2015 Dec 17.
4
Febrile neutropenia hospitalization due to pegfilgrastim on-body injector failure compared to single-injection pegfilgrastim and daily injections with reference and biosimilar filgrastim: US cost simulation for lung cancer and non-Hodgkin lymphoma.培非格司亭体注射笔故障导致的发热性中性粒细胞减少症住院治疗与单次注射培非格司亭和参照及生物类似物注射用粒细胞集落刺激因子每日注射相比：肺癌和非霍奇金淋巴瘤的美国成本模拟。
J Med Econ. 2020 Jan;23(1):28-36. doi: 10.1080/13696998.2019.1658591. Epub 2019 Sep 3.
5
Clinical efficacy and safety of mecapegfilgrastim in small cell lung cancer as primary prophylaxis of neutropenia post chemotherapy: a retrospective analysis.培格非格司亭在小细胞肺癌化疗后作为中性粒细胞减少症初级预防的临床疗效和安全性：一项回顾性分析。
Ann Palliat Med. 2021 Jul;10(7):7841-7846. doi: 10.21037/apm-21-1400.
6
Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study).使用生物类似药非格司亭预防化疗引起的（发热性）中性粒细胞减少症的治疗模式及结果（MONITOR-GCSF研究）
Support Care Cancer. 2016 Feb;24(2):911-925. doi: 10.1007/s00520-015-2861-z. Epub 2015 Aug 27.
7
Compatibility of Biosimilar Filgrastim with Cytotoxic Chemotherapy during the Treatment of Malignant Diseases (VENICE): A Prospective, Multicenter, Non-Interventional, Longitudinal Study.生物类似药非格司亭与细胞毒性化疗药物在恶性疾病治疗中的兼容性（威尼斯研究）：一项前瞻性、多中心、非干预性纵向研究
Adv Ther. 2016 Nov;33(11):1983-2000. doi: 10.1007/s12325-016-0419-1. Epub 2016 Oct 14.
8
Comparison of effectiveness of biosimilar filgrastim (Nivestim™), reference Amgen filgrastim and pegfilgrastim in febrile neutropenia primary prevention in breast cancer patients treated with neo(adjuvant) TAC: a non-interventional cohort study.生物类似药非格司亭（Nivestim™）、参比安进非格司亭和培非格司亭在接受新（辅助）TAC治疗的乳腺癌患者发热性中性粒细胞减少症一级预防中的有效性比较：一项非干预性队列研究。
Support Care Cancer. 2016 Feb;24(2):597-603. doi: 10.1007/s00520-015-2818-2. Epub 2015 Jun 27.
9
Chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim in elderly versus non-elderly cancer patients: Patterns, outcomes, and determinants (MONITOR-GCSF study).生物类似物非格司亭在老年与非老年癌症患者中预防化疗引起的（发热性）中性粒细胞减少症：模式、结局和决定因素（MONITOR-GCSF 研究）。
J Geriatr Oncol. 2017 Mar;8(2):86-95. doi: 10.1016/j.jgo.2016.09.006. Epub 2016 Nov 6.
10
Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients.生物类似药非格司亭与原研粒细胞集落刺激因子在预防乳腺癌患者发热性中性粒细胞减少症中的有效性比较
Eur J Clin Pharmacol. 2018 Mar;74(3):315-321. doi: 10.1007/s00228-017-2365-5. Epub 2017 Nov 19.

引用本文的文献

1
Impact of the national health insurance coverage policy on mecapegfilgrastim utilization for chemoradiotherapy-induced neutropenia in cancer patients in China: a retrospective real-world analysis.国家医疗保险覆盖政策对中国癌症患者放化疗引起的中性粒细胞减少症使用美泊妥珠单抗的影响：一项回顾性真实世界分析
Front Pharmacol. 2025 Feb 17;16:1546261. doi: 10.3389/fphar.2025.1546261. eCollection 2025.
2
Febrile neutropenia prophylaxis, G-CSF physician preferences: discrete-choice experiment.发热性中性粒细胞减少症的预防，粒细胞集落刺激因子（G-CSF）医生偏好：离散选择实验。
BMJ Support Palliat Care. 2021 Oct 27;14(e2). doi: 10.1136/bmjspcare-2021-003082.
3
Selection of high-producing clones by a relative titer predictive model using image analysis.使用图像分析的相对滴度预测模型筛选高产克隆。
Ann Transl Med. 2021 Jul;9(14):1144. doi: 10.21037/atm-21-2822.
4
Prophylaxis of breast cancer chemotherapy for bone marrow toxicity: more individualized and safer.乳腺癌化疗骨髓毒性的预防：更个体化且更安全。
Ann Transl Med. 2020 Feb;8(4):138. doi: 10.21037/atm.2019.12.50.

本文引用的文献

1
Efficacy and safety of mecapegfilgrastim for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer: a randomized, multicenter, active-controlled phase III trial.甲磺酸培非格司亭预防乳腺癌患者化疗引起的中性粒细胞减少症的疗效和安全性：一项随机、多中心、活性药物对照的III期试验
Ann Transl Med. 2019 Sep;7(18):482. doi: 10.21037/atm.2019.07.95.
2
A randomized multicenter phase II trial of mecapegfilgrastim single administration versus granulocyte colony-stimulating growth factor on treating chemotherapy-induced neutropenia in breast cancer patients.一项关于甲磺酸培非格司亭单次给药与粒细胞集落刺激因子治疗乳腺癌患者化疗所致中性粒细胞减少症的随机多中心II期试验。
Ann Transl Med. 2019 May;7(9):196. doi: 10.21037/atm.2019.04.10.
3
A Randomized Multicenter Phase III Study of Single Administration of Mecapegfilgrastim (HHPG-19K), a Pegfilgrastim Biosimilar, for Prophylaxis of Chemotherapy-Induced Neutropenia in Patients With Advanced Non-Small-Cell Lung Cancer (NSCLC).培非格司亭生物类似药美卡培非格司亭（HHPG-19K）单次给药用于预防晚期非小细胞肺癌（NSCLC）患者化疗所致中性粒细胞减少的随机多中心III期研究。
Clin Lung Cancer. 2016 Mar;17(2):119-27. doi: 10.1016/j.cllc.2015.12.002. Epub 2015 Dec 17.
4
Polypharmacy and health outcomes among older adults discharged from hospital: results from the CRIME study.老年患者出院后的多重用药与健康结局：CRIME研究结果
Geriatr Gerontol Int. 2015 Feb;15(2):141-6. doi: 10.1111/ggi.12241. Epub 2014 Jan 28.
5
Safety of polyethylene glycol recombinant human granulocyte colony-stimulating factor in treating non-small cell lung cancer patients at I b stage.聚乙二醇重组人粒细胞集落刺激因子治疗 Ib 期非小细胞肺癌患者的安全性。
Asian Pac J Trop Med. 2013 Nov;6(11):912-5. doi: 10.1016/S1995-7645(13)60163-7.
6
Prevention of chemotherapy-induced neutropenia with pegfilgrastim: pharmacokinetics and patient outcomes.聚乙二醇化重组人粒细胞刺激因子预防化疗引起的中性粒细胞减少症：药代动力学和患者结局。
Chemotherapy. 2012;58(5):387-98. doi: 10.1159/000345626. Epub 2012 Dec 28.
7
Modulated chemotherapy according to modified comprehensive geriatric assessment in 100 consecutive elderly patients with diffuse large B-cell lymphoma.根据改良全面老年评估对 100 例连续老年弥漫性大 B 细胞淋巴瘤患者进行的调制化疗。
Oncologist. 2012;17(6):838-46. doi: 10.1634/theoncologist.2011-0417. Epub 2012 May 18.
8
Pharmacokinetics and pharmacodynamics of pegfilgrastim.培非格司亭的药代动力学和药效学。
Clin Pharmacokinet. 2011 May;50(5):295-306. doi: 10.2165/11586040-000000000-00000.
9
Pegfilgrastim on the Same Day Versus Next Day of Chemotherapy in Patients With Breast Cancer, Non-Small-Cell Lung Cancer, Ovarian Cancer, and Non-Hodgkin's Lymphoma: Results of Four Multicenter, Double-Blind, Randomized Phase II Studies.培非格司亭在乳腺癌、非小细胞肺癌、卵巢癌和非霍奇金淋巴瘤患者中同一天与化疗后一天使用的疗效比较：四项多中心、双盲、随机 II 期研究的结果。
J Oncol Pract. 2010 May;6(3):133-40. doi: 10.1200/JOP.091094.
10
A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy.一项随机、安慰剂对照的 II 期研究，评估在接受每 2 周化疗的结直肠癌患者中，使用培非格司亭联合治疗以减少中性粒细胞减少症和发热性中性粒细胞减少症的效果。
Clin Colorectal Cancer. 2010 Apr;9(2):95-101. doi: 10.3816/CCC.2010.n.013.

A new peg-filgrastim biosimilar, mecapegfilgrastim for primary prophylaxis of chemotherapy-related neutropenia is now available.

作者信息

Tirelli Umberto, Carbone Antonino, Di Francia Raffaele, Berretta Massimiliano

机构信息

Centro di Riferimento Oncologico, Istituto Nazionale Tumori, IRCCS, Aviano (PN), Italy.

Italian Association of Pharmacogenomics and Molecular Diagnostics (IAPharmagen), Ancona, Italy.

出版信息

Ann Transl Med. 2020 Mar;8(5):166. doi: 10.21037/atm.2019.10.61.

DOI:10.21037/atm.2019.10.61
PMID:32309313
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7154413/
Abstract
摘要